<!DOCTYPE html>
<html lang="en">

<meta name="description" content="Médica intensivista pediátrica de Brasília-DF.">
<meta name="keywords"
  content="artigos de saúde, conteúdo médico, educação médica, doenças, tratamentos, prevenção, pesquisas médicas, blog de saúde, estética, pediatria, terapia intensiva pediátrica, UTIPED">
<meta name="keywords"
  content="artigos médicos, saúde, bem-estar, medicina, especialistas em saúde, consulta online, doenças, tratamentos, diagnóstico médico, telemedicina">
<meta name="robots" content="index, follow">

<head>
  
  
  
  <title>Tarefa dos checklists | Dra. Vera Meister</title>
  <link rel="canonical" href="https://www.meister.med.br/">
  <link rel='alternate' type='application/rss+xml' title="Dra. Vera Meister RSS" href='../../index.xml'>
  <link rel='stylesheet' type='text/css' href='../../style.css'>
  
  <link rel="icon" href="../../me.jpg">
  <meta name="description" content="Captopril and enalapril improve cognition and depressed mood in hypertensive patients 1



  
    
      
    
  

Este artigo foi escolhido por sua originalidade no tempo, tendo sido precursor da investigação dos impactos da hipertensão no humor. Porém, não se trata exatamente de um ensaio randomizado porque, conforme análise a seguir, isto não fica claro no desenho do estudo.
Aplicando o CONSORT2 ao estudo, segue análise:

  
      
          Section/Topic
          Item No.
          Checklist Item
          Reported on Page No.
      
  
  
      
          Title and Abstract
          1a
          Identification as a randomized trial in the title
          Não
      
      
          
          1b
          Structured summary of trial design, methods, results, and conclusions (for specific guidance, see CONSORT for abstracts)
          326-329
      
      
          Introduction
          2a
          Scientific background and explanation of rationale
          325
      
      
          
          2b
          Specific objectives or hypotheses
          323
      
      
          Methods
          3a
          Description of trial design (such as parallel, factorial), including allocation ratio
          330
      
      
          
          3b
          Important changes to methods after trial commencement (such as eligibility criteria), with reasons
          Não
      
      
          
          4a
          Eligibility criteria for participants
          326-327
      
      
          
          4b
          Settings and locations where the data were collected
          326
      
      
          
          5
          The interventions for each group with sufficient details to allow replication, including how and when they were actually administered
          Parcialmente na 326
      
      
          
          6a
          Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed
          Não
      
      
          
          6b
          Any changes to trial outcomes after the trial commenced, with reasons
          Não
      
      
          
          7a
          How sample size was determined
          Não
      
      
          
          7b
          When applicable, explanation of any interim analyses and stopping guidelines
          Não
      
      
          
          8a
          Method used to generate the random allocation sequence
          Não
      
      
          
          8b
          Type of randomization; details of any restriction (such as blocking and block size)
          Não
      
      
          
          9
          Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned
          Não
      
      
          
          10
          Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions
          Não
      
      
          
          11a
          If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how
          Participantes
      
      
          
          11b
          If relevant, description of the similarity of interventions
          326
      
      
          
          12a
          Statistical methods used to compare groups for primary and secondary outcomes
          Não
      
      
          
          12b
          Methods for additional analyses, such as subgroup analyses and adjusted analyses
          Não
      
      
          Results
          13a
          For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome
          39 participantes, pg 326
      
      
          
          13b
          For each group, losses and exclusions after randomization, together with reasons
          Não
      
      
          
          14a
          Dates defining the periods of recruitment and follow-up
          Não
      
      
          
          14b
          Why the trial ended or was stopped
          Não
      
      
          
          15
          A table showing baseline demographic and clinical characteristics for each group
          330
      
      
          
          16
          For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups
          330
      
      
          
          17a
          For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)
          330
      
      
          
          17b
          For binary outcomes, presentation of both absolute and relative effect sizes is recommended
          Não
      
      
          
          18
          Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory
          Não
      
      
          
          19
          All important harms or unintended effects in each group (for specific guidance, see CONSORT for harms)
          Não
      
      
          Discussion
          20
          Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses
          Não
      
      
          
          21
          Generalizability (external validity, applicability) of the trial findings
          Não
      
      
          
          22
          Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence
          335-336
      
      
          Other Information
          23
          Registration number and name of trial registry
          323
      
      
          
          24
          Where the full trial protocol can be accessed, if available
          Não, artigo antigo
      
      
          
          25
          Sources of funding and other support (such as supply of drugs), role of funders
          Não
      
  




Artigo observacional
Em breve">
  
  <meta name="keywords" content="doutorado">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="robots" content="index, follow">
  <meta charset="utf-8">

  
  
  <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
  
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Fira+Sans:ital,wght@0,300;0,700;1,300;1,700&display=swap"
    rel="stylesheet">
  
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Noto+Color+Emoji&display=swap" rel="stylesheet">
  
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Lavishly+Yours&display=swap" rel="stylesheet">

  
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Style+Script&display=swap" rel="stylesheet">
  <nav class=barra>
    <div>
      <div>
        <a href="../../index.html">
          <img id=logotop src="../../pix/logos/LOGOTEXTO.png"></img>
        </a>
      </div>
      <div>
        <a href="../../estetica/">ESTÉTICA</a>
        <a href="../../pediatria/">PEDIATRIA</a>
        <a href="../../nutrologia/">NUTROLOGIA</a>
      </div>
    </div>
    <Br>
    
    
  </nav>
</head>

<body>
  
  <a href= /><img class=me src=../../me.jpg>
  <figcaption>
    <span id=metxt>Dra. Vera Meister</span>
  </figcaption></img>
  </a>
  


  <article>
    
    
    <script src=../../baseof-tema.js></script>
    
    
    
    <h3 id="captopril-and-enalapril-improve-cognition-and-depressed-mood-in-hypertensive-patients">Captopril and enalapril improve cognition and depressed mood in hypertensive patients <sup id="fnref:1"><a href="#fn:1" class="footnote-ref" role="doc-noteref">1</a></sup></h3>
<p>


  <div id="img-div">
    <img class=mediaframe src="../../pix/doutorado/captopril.png">
      <figcaption></figcaption>
    </img>
  </div>

Este artigo foi escolhido por sua originalidade no tempo, tendo sido precursor da investigação dos impactos da hipertensão no humor. Porém, não se trata exatamente de um ensaio randomizado porque, conforme análise a seguir, isto não fica claro no desenho do estudo.</p>
<p>Aplicando o CONSORT<sup id="fnref:2"><a href="#fn:2" class="footnote-ref" role="doc-noteref">2</a></sup> ao estudo, segue análise:</p>
<table>
  <thead>
      <tr>
          <th>Section/Topic</th>
          <th>Item No.</th>
          <th>Checklist Item</th>
          <th>Reported on Page No.</th>
      </tr>
  </thead>
  <tbody>
      <tr>
          <td><strong>Title and Abstract</strong></td>
          <td>1a</td>
          <td>Identification as a randomized trial in the title</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>1b</td>
          <td>Structured summary of trial design, methods, results, and conclusions (for specific guidance, see CONSORT for abstracts)</td>
          <td>326-329</td>
      </tr>
      <tr>
          <td><strong>Introduction</strong></td>
          <td>2a</td>
          <td>Scientific background and explanation of rationale</td>
          <td>325</td>
      </tr>
      <tr>
          <td></td>
          <td>2b</td>
          <td>Specific objectives or hypotheses</td>
          <td>323</td>
      </tr>
      <tr>
          <td><strong>Methods</strong></td>
          <td>3a</td>
          <td>Description of trial design (such as parallel, factorial), including allocation ratio</td>
          <td>330</td>
      </tr>
      <tr>
          <td></td>
          <td>3b</td>
          <td>Important changes to methods after trial commencement (such as eligibility criteria), with reasons</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>4a</td>
          <td>Eligibility criteria for participants</td>
          <td>326-327</td>
      </tr>
      <tr>
          <td></td>
          <td>4b</td>
          <td>Settings and locations where the data were collected</td>
          <td>326</td>
      </tr>
      <tr>
          <td></td>
          <td>5</td>
          <td>The interventions for each group with sufficient details to allow replication, including how and when they were actually administered</td>
          <td>Parcialmente na 326</td>
      </tr>
      <tr>
          <td></td>
          <td>6a</td>
          <td>Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>6b</td>
          <td>Any changes to trial outcomes after the trial commenced, with reasons</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>7a</td>
          <td>How sample size was determined</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>7b</td>
          <td>When applicable, explanation of any interim analyses and stopping guidelines</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>8a</td>
          <td>Method used to generate the random allocation sequence</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>8b</td>
          <td>Type of randomization; details of any restriction (such as blocking and block size)</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>9</td>
          <td>Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>10</td>
          <td>Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>11a</td>
          <td>If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how</td>
          <td>Participantes</td>
      </tr>
      <tr>
          <td></td>
          <td>11b</td>
          <td>If relevant, description of the similarity of interventions</td>
          <td>326</td>
      </tr>
      <tr>
          <td></td>
          <td>12a</td>
          <td>Statistical methods used to compare groups for primary and secondary outcomes</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>12b</td>
          <td>Methods for additional analyses, such as subgroup analyses and adjusted analyses</td>
          <td>Não</td>
      </tr>
      <tr>
          <td><strong>Results</strong></td>
          <td>13a</td>
          <td>For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome</td>
          <td>39 participantes, pg 326</td>
      </tr>
      <tr>
          <td></td>
          <td>13b</td>
          <td>For each group, losses and exclusions after randomization, together with reasons</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>14a</td>
          <td>Dates defining the periods of recruitment and follow-up</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>14b</td>
          <td>Why the trial ended or was stopped</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>15</td>
          <td>A table showing baseline demographic and clinical characteristics for each group</td>
          <td>330</td>
      </tr>
      <tr>
          <td></td>
          <td>16</td>
          <td>For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups</td>
          <td>330</td>
      </tr>
      <tr>
          <td></td>
          <td>17a</td>
          <td>For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)</td>
          <td>330</td>
      </tr>
      <tr>
          <td></td>
          <td>17b</td>
          <td>For binary outcomes, presentation of both absolute and relative effect sizes is recommended</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>18</td>
          <td>Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>19</td>
          <td>All important harms or unintended effects in each group (for specific guidance, see CONSORT for harms)</td>
          <td>Não</td>
      </tr>
      <tr>
          <td><strong>Discussion</strong></td>
          <td>20</td>
          <td>Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>21</td>
          <td>Generalizability (external validity, applicability) of the trial findings</td>
          <td>Não</td>
      </tr>
      <tr>
          <td></td>
          <td>22</td>
          <td>Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence</td>
          <td>335-336</td>
      </tr>
      <tr>
          <td><strong>Other Information</strong></td>
          <td>23</td>
          <td>Registration number and name of trial registry</td>
          <td>323</td>
      </tr>
      <tr>
          <td></td>
          <td>24</td>
          <td>Where the full trial protocol can be accessed, if available</td>
          <td>Não, artigo antigo</td>
      </tr>
      <tr>
          <td></td>
          <td>25</td>
          <td>Sources of funding and other support (such as supply of drugs), role of funders</td>
          <td>Não</td>
      </tr>
  </tbody>
</table>
<br>
<br>
<br>
<h2 id="artigo-observacional">Artigo observacional</h2>
<p>Em breve</p>
<h2 id="artigo-revisão-sistemática">Artigo revisão sistemática</h2>
<p>Em breve</p>
<!-- 


  <div id="img-div">
    <img class=mediaframe src="../../pix/">
      <figcaption></figcaption>
    </img>
  </div>
 -->
<!-- 


  <div id="img-div">
    <img class=mediaframe src="../../pix/">
      <figcaption></figcaption>
    </img>
  </div>
 -->
<div class="footnotes" role="doc-endnotes">
<hr>
<ol>
<li id="fn:1">
<p>Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR. <strong>Captopril and enalapril improve cognition and depressed mood in hypertensive patients</strong>. J Basic Clin Physiol Pharmacol. 2003;14(4):323-43. doi: 10.1515/jbcpp.2003.14.4.323. PMID: 15198305.&#160;<a href="#fnref:1" class="footnote-backref" role="doc-backlink">&#x21a9;&#xfe0e;</a></p>
</li>
<li id="fn:2">
<p>Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., &amp; Altman, D. G. (2010). <strong>CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials</strong>. BMJ, 340, c869. <a href="https://doi.org/10.1136/bmj.c869">https://doi.org/10.1136/bmj.c869</a>&#160;<a href="#fnref:2" class="footnote-backref" role="doc-backlink">&#x21a9;&#xfe0e;</a></p>
</li>
</ol>
</div>

    
    
    <br>
<div style="" class=taglist>
  <a id="tag_doutorado" href="https://www.meister.med.br/tags/doutorado">doutorado</a></div>
    <br>
    <br>
    <br>
    <br>
    <br>
    <br>
    <br>
    <br>
    <hr>
    <div id=notas>
      <div>
        <p><span style="color: white">Dra. Vera Meister</span> é médica pediatra intensivista há mais de 20
          anos.<br>Atua na medicina integrativa desde que se especializou em nutrologia médica e tem treinamento e
          formação para realizar a maioria dos procedimentos estéticos existentes no mercado.<br>Seu currículo completo
          pode ser acesso <a href=../../cv />aqui</a>.</p>
      </div>
      <div>
        <p><span style="color: white">Aviso:</span><br>Todo o conteúdo deste <i>website</i> tem caráter informacional ou
          comercial e são protegidos por
          direitos autorais da proprietária.</p>
      </div>
      <div>
        <p><span style="color: white">Contato</span>: meister.med@me.com<br> <span style="color: white">Endereço</span>:
          SHLN Bloco G Lote 09 - Ed.Biosphere Health Center Torre A, Salas
          203 e 205 - Asa Norte, Brasília - DF, 70770-560<br> <span style="color: white">Webmaster</span>:
          contato@jefferson.med.br<br>
        <p>
      </div>
    </div>
    
    
    <br>
    <div class=aoInicio>
      <a href="https://www.meister.med.br/"> Início</a>
    </div>
    <br>
    <div class=aoTopo>
      <a href='#' onClick="retornaTopo()"><b><span class="material-icons">vertical_align_top</span></b></a>
    </div>
    <script>
      function retornaTopo() {
        document.documentElement.scrollTop = 0;
      }
    </script>
  </article>
  <footer>
    <hr>
    <br>
    <a href="https://www.jeffersontorres.com.br">Desenvolvido por Jefferson T. - @fatiservae - 2025 </a>
    <br>
    <br>
    <br>
  </footer>
  
</body>

</html>